News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
The European regulator will conduct a re-inspection of the facility to verify the compliance
There are 38.4 million people with diabetes in the United States
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
USFDA inspection at Emcure Pharmaceuticals API facility
Subscribe To Our Newsletter & Stay Updated
